WO2018027524A1 - Formule d'anticorps anti-pd-1. - Google Patents

Formule d'anticorps anti-pd-1. Download PDF

Info

Publication number
WO2018027524A1
WO2018027524A1 PCT/CN2016/094094 CN2016094094W WO2018027524A1 WO 2018027524 A1 WO2018027524 A1 WO 2018027524A1 CN 2016094094 W CN2016094094 W CN 2016094094W WO 2018027524 A1 WO2018027524 A1 WO 2018027524A1
Authority
WO
WIPO (PCT)
Prior art keywords
concentration
antibody
present
formulation
pharmaceutical formulation
Prior art date
Application number
PCT/CN2016/094094
Other languages
English (en)
Inventor
Wei Cao
Junfeng Li
Xiaolin Liu
Original Assignee
Innovent Biologics (Suzhou) Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics (Suzhou) Co., Ltd. filed Critical Innovent Biologics (Suzhou) Co., Ltd.
Priority to PCT/CN2016/094094 priority Critical patent/WO2018027524A1/fr
Priority to CA3030929A priority patent/CA3030929C/fr
Priority to JP2019507084A priority patent/JP6848046B2/ja
Priority to ES17838513T priority patent/ES2969233T3/es
Priority to US16/322,630 priority patent/US11130809B2/en
Priority to BR112019001233-8A priority patent/BR112019001233B1/pt
Priority to PCT/CN2017/093141 priority patent/WO2018028383A1/fr
Priority to CN201780049042.6A priority patent/CN109562173B/zh
Priority to AU2017310916A priority patent/AU2017310916B2/en
Priority to EP17838513.4A priority patent/EP3496753B1/fr
Publication of WO2018027524A1 publication Critical patent/WO2018027524A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

  • the present invention relates to the field of medicine. More particularly, the present invention relates to a pharmaceutical formulation of an anti-human programmed cell death 1 (anti-PD-1) antibody.
  • This anti-PD-1 antibody pharmaceutical formulation is expected to be useful in treating cancers that respond to anti-PD-1 antibodies as a monotherapy and in combination with chemotherapy and other cancer therapeutics.
  • compositions of anti-PD-1 antibodies are needed for the treatment of patients with cancer. Certain concentrations of anti-PD-1 antibodies are needed for pharmaceutical formulations so that the antibody can be delivered intra-venously to the patient.
  • This pharmaceutical formulation with a certain concentration of the anti-PD-1 antibody must maintain physical and chemical stability of the anti-PD-1 antibody over long periods of time in storage.
  • the formulation should not only maintain stability of the anti-PD-1 antibody for periods of time at room temperature, but maintain stability under possible fluctuations in temperature and under potential exposures to light.
  • Anti-PD-1 antibodies used in the present pharmaceutical formulations are disclosed in PCT/CN2015/086494. Those antibodies were discovered to be prone to chemical instability, including oxidation, when stored over a long period of time and under various environmental conditions. Thus, pharmaceutical formulations for anti-PD-1 antibodies are needed that avoid these observed problems and also demonstrate stability during extended shelf life.
  • the present invention provides a pharmaceutical formulation comprising an anti-PD-1 antibody at a concentration in the range of about 5 mg/mL to about 15 mg/mL, citrate at a concentration of about 15 mM to about 25 mM, histidine at a concentration of about 20 mM to about 30 mM, mannitol at a concentration of about 130 mM to about 165 mM, sodium chloride at a concentration of about 45 mM to about 55 mM, edetate at a concentration of about 0.01 mM to about 0.03 mM, polysorbate 20 or polysorbate 80 at a concentration in the range of about 0.01%to about 0.03%, and pH of about 5.5 to about 6.5, wherein the anti-PD-1 antibody comprises two light chains (LCs) and two heavy chains (HCs) , wherein the amino acid sequence of both LCs is SEQ ID NO: 2 and the amino acid sequence of both HCs is the same and is either SEQ ID NO: 3 or SEQ ID NO
  • the present invention also provides a pharmaceutical formulation comprising an anti-PD-1 antibody at a concentration of about 10 mg/mL, citrate at a concentration of about 15 mM to about 25 mM, histidine at a concentration of about 20 mM to about 30 mM, mannitol at a concentration of about 130 mM to about 165 mM, sodium chloride at a concentration of about 45 mM to about 55 mM, edetate at a concentration of about 0.01 mM to about 0.03 mM, polysorbate 20 or polysorbate 80 at a concentration in the range of about 0.01%to about 0.03%, and pH of about 5.5 to about 6.5, wherein the anti-PD-1 antibody comprises two light chains (LCs) and two heavy chains (HCs) , wherein the amino acid sequence of both LCs is SEQ ID NO: 2 and the amino acid sequence of both HCs is the same and is either SEQ ID NO: 3 or SEQ ID NO: 4.
  • LCs light chains
  • the present invention also provides a pharmaceutical formulation comprising an anti-PD-1 antibody at a concentration in the range of about 5 mg/mL to about 15 mg/mL, citrate at a concentration of about 20 mM, histidine at a concentration of about 20 mM to about 30 mM, mannitol at a concentration of about 130 mM to about 165 mM, sodium chloride at a concentration of about 45 mM to about 55 mM, edetate at a concentration of about 0.01 mM to about 0.03 mM, polysorbate 20 or polysorbate 80 at a concentration in the range of about 0.01%to about 0.03%, and pH of about 5.5 to about 6.5, wherein the anti-PD-1 antibody comprises two light chains (LCs) and two heavy chains (HCs) , wherein the amino acid sequence of both LCs is SEQ ID NO: 2 and the amino acid sequence of both HCs is the same and is either SEQ ID NO: 3 or SEQ ID NO: 4.
  • LCs
  • the present invention also provides a pharmaceutical formulation comprising an anti-PD-1 antibody at a concentration in the range of about 5 mg/mL to about 15 mg/mL, citrate at a concentration of about 15 mM to about 25 mM, histidine at a concentration of about 25 mM, mannitol at a concentration of about 130 mM to about 165 mM, sodium chloride at a concentration of about 45 mM to about 55 mM, edetate at a concentration of about 0.01 mM to about 0.03 mM, polysorbate 20 or polysorbate 80 at a concentration in the range of about 0.01%to about 0.03%, and pH of about 5.5 to about 6.5, wherein the anti-PD-1 antibody comprises two light chains (LCs) and two heavy chains (HCs) , wherein the amino acid sequence of both LCs is SEQ ID NO: 2 and the amino acid sequence of both HCs is the same and is either SEQ ID NO: 3 or SEQ ID NO: 4.
  • LCs
  • the present invention also provides a pharmaceutical formulation comprising an anti-PD-1 antibody at a concentration in the range of about 5 mg/mL to about 15 mg/mL, citrate at a concentration of about 15 mM to about 25 mM, histidine at a concentration of about 20 mM to about 30 mM, mannitol at a concentration of about 140 mM, sodium chloride at a concentration of about 45 mM to about 55 mM, edetate at a concentration of about 0.01 mM to about 0.03 mM, polysorbate 20 or polysorbate 80 at a concentration in the range of about 0.01%to about 0.03%, and pH of about 5.5 to about 6.5, wherein the anti-PD-1 antibody comprises two light chains (LCs) and two heavy chains (HCs) , wherein the amino acid sequence of both LCs is SEQ ID NO: 2 and the amino acid sequence of both HCs is the same and is either SEQ ID NO: 3 or SEQ ID NO: 4.
  • LCs light
  • the present invention also provides a pharmaceutical formulation comprising an anti-PD-1 antibody at a concentration in the range of about 5 mg/mL to about 15 mg/mL, citrate at a concentration of about 15 mM to about 25 mM, histidine at a concentration of about 20 mM to about 30 mM, mannitol at a concentration of about 130 mM to about 165 mM, sodium chloride at a concentration of about 50 mM, edetate at a concentration of about 0.01 mM to about 0.03 mM, polysorbate 20 or polysorbate 80 at a concentration in the range of about 0.01%to about 0.03%, and pH of about 5.5 to about 6.5, wherein the anti-PD-1 antibody comprises two light chains (LCs) and two heavy chains (HCs) , wherein the amino acid sequence of both LCs is SEQ ID NO: 2 and the amino acid sequence of both HCs is the same and is either SEQ ID NO: 3 or SEQ ID NO: 4.
  • LCs
  • the present invention provides a pharmaceutical formulation comprising an anti-PD-1 antibody at a concentration in the range of about 5 mg/mL to about 15 mg/mL, citrate at a concentration of about 15 mM to about 25 mM, histidine at a concentration of about 20 mM to about 30 mM, mannitol at a concentration of about 130 mM to about 165 mM, sodium chloride at a concentration of about 45 mM to about 55 mM, edetate at a concentration of about 0.02 mM, polysorbate 20 or polysorbate 80 at a concentration in the range of about 0.01%to about 0.03%, and pH of about 5.5 to about 6.5, wherein the anti-PD-1 antibody comprises two light chains (LCs) and two heavy chains (HCs) , wherein the amino acid sequence of both LCs is SEQ ID NO: 2 and the amino acid sequence of both HCs is the same and is either SEQ ID NO: 3 or SEQ ID NO: 4.
  • LCs light chains
  • the present invention also provides a pharmaceutical formulation comprising an anti-PD-1 antibody at a concentration in the range of about 5 mg/mL to about 15 mg/mL, citrate at a concentration of about 15 mM to about 25 mM, histidine at a concentration of about 20 mM to about 30 mM, mannitol at a concentration of about 130 mM to about 165 mM, sodium chloride at a concentration of about 45 mM to about 55 mM, edetate at a concentration of about 0.01 mM to about 0.03 mM, polysorbate 20 or polysorbate 80 at a concentration of about 0.02%, and pH of about 5.5 to about 6.5, wherein the anti-PD-1 antibody comprises two light chains (LCs) and two heavy chains (HCs) , wherein the amino acid sequence of both LCs is SEQ ID NO: 2 and the amino acid sequence of both HCs is the same and is either SEQ ID NO: 3 or SEQ ID NO: 4.
  • LCs light chains
  • the present invention also provides a pharmaceutical formulation comprising an anti-PD-1 antibody at a concentration in the range of about 5 mg/mL to about 15 mg/mL, citrate at a concentration of about 15 mM to about 25 mM, histidine at a concentration of about 20 mM to about 30 mM, mannitol at a concentration of about 130 mM to about 165 mM, sodium chloride at a concentration of about 45 mM to about 55 mM, edetate at a concentration of about 0.01 mM to about 0.03 mM, polysorbate 20 or polysorbate 80 at a concentration in the range of about 0.01%to about 0.03%, and pH of about 6.0, wherein the anti-PD-1 antibody comprises two light chains (LCs) and two heavy chains (HCs) , wherein the amino acid sequence of both LCs is SEQ ID NO: 2 and the amino acid sequence of both HCs is the same and is either SEQ ID NO: 3 or SEQ ID NO: 4.
  • the present invention also provides a pharmaceutical formulation comprising an anti-PD-1 antibody at a concentration of about 10 mg/mL, citrate at a concentration of about 20 mM, histidine at a concentration of about 25 mM, mannitol at a concentration of about 140 mM, sodium chloride at a concentration of about 50 mM, edetate at a concentration of about 0.02 mM, polysorbate-80 at a concentration of about 0.02%, and pH at about 6.0, wherein the anti-PD-1 antibody comprises two light chains (LCs) and two heavy chains (HCs) , wherein the amino acid sequence of both LCs is SEQ ID NO: 2 and the amino acid sequence of both HCs is the same and is either SEQ ID NO: 3 or SEQ ID NO: 4.
  • LCs light chains
  • HCs heavy chains
  • the present invention also provides a pharmaceutical formulation comprising an anti-PD-1 antibody at a concentration of about 10 mg/mL, citrate at a concentration of about 20 mM, histidine at a concentration of about 25 mM, mannitol at a concentration of about 140 mM, sodium chloride at a concentration of about 50 mM, edetate at a concentration of about 0.02 mM, polysorbate-20 at a concentration of about 0.02%, and pH at about 6.0, wherein the anti-PD-1 antibody comprises two light chains (LCs) and two heavy chains (HCs) , wherein the amino acid sequence of both LCs is SEQ ID NO: 2 and the amino acid sequence of both HCs is the same and is either SEQ ID NO: 3 or SEQ ID NO: 4.
  • LCs light chains
  • HCs heavy chains
  • the present invention also provides a pharmaceutical formulation that comprises a concentration of anti-PD-1 antibody of about 5 mg/mL to about 15 mg/mL. In another embodiment, the present invention provides a pharmaceutical formulation that comprises a concentration of anti-PD-1 antibody of about 5 mg/mL. In another embodiment, the present invention provides a pharmaceutical formulation that comprises a concentration of anti-PD-1 antibody of about 10 mg/mL. In another embodiment, the present invention provides a pharmaceutical formulation that comprises a concentration of anti-PD-1 antibody of about 15 mg/mL.
  • the present invention also provides a pharmaceutical formulation that is buffered with citrate in the range of about 15 mM to about 25 mM. In another embodiment, the present invention provides a pharmaceutical formulation that is buffered with citrate in the range of 15 mM to 25 mM. In another embodiment, the present invention provides a pharmaceutical formulation that is buffered with citrate at a concentration of about 15 mM, about 20 mM, or about 25 mM. In a further embodiment, the present invention provides a pharmaceutical formulation that is buffered with citrate at a concentration of about 20 mM.
  • the present invention provides a pharmaceutical formulation that is buffered with histidine in the range of 20 mM to 30 mM. In another embodiment, the present invention provides a pharmaceutical formulation that is buffered with histidine at a concentration of about 20 mM, about 25 mM, or about 30 mM. In a further embodiment, the present invention provides a pharmaceutical formulation that is buffered with histidine at a concentration of about 25 mM.
  • the present invention also provides a pharmaceutical formulation that comprises a concentration of mannitol of about 130 mM to about 165 mM.
  • the present invention provides a pharmaceutical formulation that comprises a concentration of mannitol of about 130 mM, about 135 mM, about 140 mM, about 145 mM, about 150 mM, about 155 mM, about 160 mM, or about 165 mM.
  • the present invention provides a pharmaceutical formulation that comprises a concentration of mannitol of about 140 mM.
  • the present invention also provides a pharmaceutical formulation that comprises a concentration of NaCl of about 45 mM to about 55 mM. In another embodiment, the present invention provides a pharmaceutical formulation that comprises a concentration of NaCl of about 45 mM, about 50 mM, or about 55 mM. In a further embodiment, the present invention provides a pharmaceutical formulation that comprises a concentration of NaCl of about 50 mM.
  • the present invention also provides a pharmaceutical formulation that comprises a concentration of edetate of about 0.01 mM to about 0.03 mM. In another embodiment, the present invention provides a pharmaceutical formulation that comprises a concentration of disodium edetate of about 0.01 mM, about 0.015 mM, about 0.02 mM, about 0.025 mM, or about 0.03 mM. In a further embodiment, the present invention provides a pharmaceutical formulation that comprises a concentration of disodium edetate of about 0.02 mM.
  • the present invention also provides a pharmaceutical formulation that comprises a concentration of polysorbate-80 or polysorbate-20 of about 0.01%to about 0.03%. In another embodiment, the present invention provides a pharmaceutical formulation that comprises a concentration of polysorbate-80 of about 0.01%, about 0.015%, about 0.02%, about 0.025%, or about 0.03%. In a further embodiment, the present invention provides a pharmaceutical formulation that comprises a concentration of polysorbate-80 of about 0.02%.
  • the present invention also provides a pharmaceutical formulation within a pH range of about 5.5 to about 6.5. In another embodiment, the present invention provides a pharmaceutical formulation that comprises a pH of about 5.5, about 6.0, or about 6.5. In a further embodiment, the present invention provides a pharmaceutical formulation that comprises a pH of about 6.0.
  • the anti-PD-1 antibody comprises an antibody comprising two light chains (LCs) and two heavy chains (HCs) , wherein each LC is the amino acid sequence of SEQ ID NO: 2 and each HC is the amino acid sequence of SEQ ID NO: 3 or the amino acid sequence of SEQ ID NO: 4;
  • the anti-PD-1 antibody at a concentration of about 5 mg/mL to about 15 mg/mL;
  • the anti-PD-1 antibody at a concentration of about 10 mg/mL
  • polysorbate-80 is at a concentration of about 0.01%to about 0.03%
  • polysorbate-80 is at a concentration of about 0.02%
  • polysorbate-20 is at a concentration of about 0.01%to about 0.03%
  • polysorbate-20 is at a concentration of about 0.02%
  • citrate is at a concentration of about 15 mM to about 25 mM
  • citrate is at a concentration of about 20 mM
  • histidine is at a concentration of about 20 mM to about 30 mM;
  • histidine is at a concentration of about 25 mM
  • mannitol is at a concentration of about 130 mM to about 165 mM;
  • mannitol is at a concentration of about 140 mM
  • sodium chloride is at a concentration of about 45 mM to about 55 mM;
  • sodium chloride is at a concentration of about 50 mM
  • edetate is at a concentration in the range of about 0.01 to about 0.03 mM.
  • edetate is at a concentration of about 0.02 mM
  • histidine is at a concentration of about 25 mM and citrate at a concentration of about 20 mM.
  • the pH is 5.5 to 6.5.
  • the pH is about 6.0.
  • the present invention provides a method of treating cancers that may respond to anti-PD-1 antibodies comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation described herein.
  • the method of treating cancer comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation of the present invention, wherein the cancer is selected from the group of melanoma, lung cancer, head and neck cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer, ovarian cancer, or hepatocellular carcinoma.
  • the present invention provides a method of treating melanoma comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation of the present invention.
  • the present invention provides a method of treating lung cancer comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation of the present invention. Also, the present invention provides a method of treating head and neck comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation of the present invention. Also, the present invention provides a method of treating colorectal cancer comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation of the present invention. Also, the present invention provides a method of treating pancreatic cancer comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation of the present invention. Also, the present invention provides a method of treating gastric cancer comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation of the present invention.
  • the present invention provides a method of treating kidney cancer comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation of the present invention. Also, the present invention provides a method of treating bladder cancer comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation of the present invention. Also, the present invention provides a method of treating prostate cancer comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation of the present invention. Also, the present invention provides a method of treating breast cancer comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation of the present invention. Also, the present invention provides a method of treating ovarian cancer comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation of the present invention.
  • the present invention provides a method of treating hepatocellular carcinoma comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation of the present invention.
  • the present invention provides the pharmaceutical formulation of the present invention for use in treating cancer.
  • the present invention provides the pharmaceutical formulation of the present invention for use in the treatment of melanoma, lung cancer, head and neck cancer, colorectal cancer, pancreatic cancer, gastric cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer, ovarian cancer, or hepatocellular carcinoma. More particularly, the present invention provides the pharmaceutical formulation of the present invention for use in the treatment of melanoma. Also, the present invention provides the pharmaceutical formulation of the present invention for use in the treatment of lung cancer.
  • the present invention provides the pharmaceutical formulation of the present invention for use in the treatment of head and neck cancer. Also, the present invention provides the pharmaceutical formulation of the present invention for use in the treatment of colorectal cancer. Also, the present invention provides the pharmaceutical formulation of the present invention for use in the treatment of gastric cancer. Also, the present invention provides the pharmaceutical formulation of the present invention for use in the treatment of colorectal cancer. Also, the present invention provides the pharmaceutical formulation of the present invention for use in the treatment of kidney cancer. Also, the present invention provides the pharmaceutical formulation of the present invention for use in the treatment of bladder cancer. Also, the present invention provides the pharmaceutical formulation of the present invention for use in the treatment of prostate cancer. Also, the present invention provides the pharmaceutical formulation of the present invention for use in the treatment of breast cancer. Also, the present invention provides the pharmaceutical formulation of the present invention for use in the treatment of ovarian cancer. Also, the present invention provides the pharmaceutical formulation of the present invention for use in the treatment of hepatocellular carcinoma.
  • the pharmaceutical formulations of the present invention comprise citrate.
  • Citrate can be made using one or more of citric acid, trisodium citrate dihydrate, and citric acid monohydrate; or citric acid monohydrate, sodium phosphate dibasic, and citric acid.
  • citrate can be made comprising sodium citrate monobasic, citric acid trisodium salt, or sodium citrate tribasic hydrate.
  • citrate is made with sodium citrate dihydrate and citric acid.
  • Other counterions besides sodium may be used.
  • the pharmaceutical formulations of the present invention comprise edetate.
  • edetate is edetate disodium (EDTA. 2Na) .
  • Antibody 1 is an anti-PD-1 antibody comprising two light chains (LCs) and two heavy chains (HCs) , wherein the amino acid sequence of each LC is SEQ ID NO: 2 and the amino acid sequence of each HC is SEQ ID NO: 3.
  • Antibody 2 is an anti-PD-1 antibody comprising two light chains (LCs) and two heavy chains (HCs) , wherein the amino acid sequence of each LC is SEQ ID NO: 2 and the amino acid sequence of each HC is SEQ ID NO: 4.
  • An anti-PD-1 antibody for use in the formulations of the present invention can be produced using techniques well known in the art, e.g., recombinant technologies, phage display technologies, synthetic technologies, or combinations of such technologies or other technologies readily known in the art. Methods for producing and purifying antibodies and antigen-binding fragments are well known in the art and can be found, for example, in Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, chapters 5-8 and 15, ISBN 0-87969-314-2.
  • Antibodies 1 and 2 can be prepared in mammalian expression systems that are commonly used for industrial-scale cell culture using ordinary skill in the antibody art. As expressed in such common mammalian expression systems, such as CHO or NS0, the expressed antibodies will have the expected disulfide bonds within and between the chains. Furthermore, the antibodies will be glycosylated within CH2.
  • an antibody in solution must have sufficient chemical stability and physical stability.
  • Oxidation, deamidation, and hydrolysis are examples of chemical stability issues that an antibody can have in a formulation.
  • Aggregation and gel formation are examples of physical stability issues that an antibody can have in a formulation.
  • a pharmaceutical formulation of an antibody is considered stable if the degree of degradation, modification, aggregation, loss of biological activity and the like, of the antibody therein is acceptably controlled and does not increase unacceptably with time. Stability may be assessed by methods well-known in the art, including measurement of a sample's light scattering, apparent attenuation of light (absorbance, or optical density) , size of aggregates or other polymerized forms of the antibody (e.g.
  • SEC size exclusion chromatography
  • DSC differential scanning calorimetry
  • the present invention provides a method of treating cancers that may respond to anti-PD-1 antibodies comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation described herein.
  • An effective amount of the anti-PD-1 antibody formulation of the present invention is the quantity that when administered to a patient in need of treatment results in the desired therapeutic effect without causing unacceptable side-effects when administered to a subject with increased PD-1 levels.
  • Solid buffer ingredients are weighed and transferred to a beaker to which 80%of the target volume of dd H 2 O is added and the mixture is stirred with a magnetic stirrer to dissolve the ingredients. After all ingredients are dissolved, the pH of the solution is adjusted to 6.0 using 2 M citric acid and dd H 2 O is added to achieve the target volume. Polysorbate 80 is then prepared at 20 mg/mL using the initial buffer to attain a 100x concentration of polysorbate 80. Antibody samples are concentrated to about 15 mg/mL using an Amicon Ultra-30K centrifugal filter at 3800 g. Concentrated antibody samples are subjected to 6-7 rounds of buffer-exchange in the initial buffer.
  • Buffer exchanged antibody samples are diluted with the initial buffer and 100x polysorbate 80 to achieve a final concentration of 10 mg/mL of antibody and 0.2 mg/mL of polysorbate 80. Samples are sterile filtered with 0.22 ⁇ m filter to obtain the final drug product.
  • samples of Antibody 1 are analyzed in citrate buffer at varying pH.
  • the citrate buffer is prepared at 10 mM in double-distilled water (dd H 2 O) and the pH of the buffer is adjusted to a pH of 4, 5, 6, 7 or 8.
  • Antibody 1 is diluted at 5 mg/mL in the various pH adjusted citrate buffers and is incubated at 37 °C for 10 days.
  • the samples are tested at Day 0 and Day 10 via SEC-HPLC (Size Exclusion Chromatography-High Performance Liquid Chromatography) as per the Pharmacopoeia of the People's Republic of China, (Edition 2010, Section 3, Appendix IIIB) , and are detected via hydrophilic silica gel size exclusion columns, and sample purity is measured by area normalization.
  • the Day 0 main peak area % was 98.65%.
  • Antibody 1 solution formulations are prepared according to Table 4.
  • Phosphate buffer and Citrate buffer are prepared in dd H 2 O at 20 mM.
  • Various test excipients as shown in Table 4 are tested to determine the optimal formulation for Antibody 1. Excipients are added to the various buffers and the pH is adjusted to 6.0 for each sample. Test samples are incubated at 25°C for up to three months.
  • Samples are tested for stability at Day 0, and at Months 1 and 3via CEX-HPLC (Ion Exchange Chromatography-High Performance Liquid Chromatography) as per the Pharmacopoeia of the People's Republic of China, (Edition 2010, Section three, Appendix IIIB) , and is detected with cation columns, and sample purity is measured by area normalization. The results are illustrated in Table 5.
  • CEX-HPLC Ion Exchange Chromatography-High Performance Liquid Chromatography
  • Each tested formulation comprised 10 mg/mL of Antibody 1, 50 mM sodium chloride, and 0.02%polysorbate, and each had its pH adjusted to 6.0.
  • formulation test samples F2 and F6 have a slower increase in acidic species, which not only indicates that the formulation of F2 and F6 provided a more stable environment for Antibody 1 when compared to the other formulations tested, but surprisingly showed that the unique combination of polysorbate 80, mannitol and histidine in citrate buffer provide enhanced stability for Antibody 1.
  • test samples F2 and F6 are duplicated to test for light sensitivity testing of Antibody 1.
  • Test samples F2 and F6 containing Antibody 1 at 10 mg/mL are exposed to a high intensity fluorescent light (5000 Lux) at 25°C for 10 days.
  • the samples are tested for stability at Day 0, Day 5 and Day 10 using CEX-HPLC and SEC-HPLC technology.
  • test sample F6 provides greater anti-oxidative properties for Antibody 1 when compared to formulation test sample F2 and consequently resulting in enhanced stability and anti-oxidation properties for Antibody 1.
  • Biologic drug products are stored at 5°C ⁇ 3 °C to minimize chemical and physical degradation over the shelf-life of a product.
  • Antibody 1 at 10 mg/mL is tested for long-term stability in the formulation F6.
  • Antibody 1 is aseptically dispensed in to vials, and is sealed with rubber stoppers and plastic covers and is incubated at 2°C to about 8°C for 11 months. The samples are tested for stability at Day 0 and at 3, 6 and 11 month time points using CEX-HPLC and SEC-HPLC technology
  • Antibody 1 at 10 mg/mL is tested for freeze-thaw stability in the formulation F6.
  • Antibody 1 in the aforementioned formulation in Example 5 is aseptically dispensed in to glass vials, and is sealed with rubber stoppers and plastic covers and is incubated at -80 °C followed by a thaw cycle at room temperature. The freeze-thaw cycle is repeated up to 6 times for the same sample. The samples are tested for stability prior to freezing, and at the 3 rd and 6 th thaw cycles, using CEX-HPLC and SEC-HPLC technology.
  • a new and unique formulation with an unexpected combination of ingredients that provide properties which can improve the physical and chemical stability of the anti-PD-1 antibody, by providing anti-oxidative properties, extending shelf life, and potentially enhancing the clinical safety of the antibody.
  • a unique formulation which enables the anti-PD-1 antibody to maintain chemical and physical stability under strenuous conditions, and varying temperatures ranging from 2-8°C, 25°C, 37°C and -80°C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur une formule pharmaceutique d'anticorps anti-PD-1.
PCT/CN2016/094094 2016-08-09 2016-08-09 Formule d'anticorps anti-pd-1. WO2018027524A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
PCT/CN2016/094094 WO2018027524A1 (fr) 2016-08-09 2016-08-09 Formule d'anticorps anti-pd-1.
CA3030929A CA3030929C (fr) 2016-08-09 2017-07-17 Formulation d'anticorps anti-pd-1
JP2019507084A JP6848046B2 (ja) 2016-08-09 2017-07-17 Ｐｄ−１抗体製剤
ES17838513T ES2969233T3 (es) 2016-08-09 2017-07-17 Formulación de anticuerpos anti-Pd-1
US16/322,630 US11130809B2 (en) 2016-08-09 2017-07-17 PD-1 antibody formulation
BR112019001233-8A BR112019001233B1 (pt) 2016-08-09 2017-07-17 Formulação farmacêutica e uso da mesma
PCT/CN2017/093141 WO2018028383A1 (fr) 2016-08-09 2017-07-17 Formulation d'anticorps anti-pd-1
CN201780049042.6A CN109562173B (zh) 2016-08-09 2017-07-17 Pd-1抗体制剂
AU2017310916A AU2017310916B2 (en) 2016-08-09 2017-07-17 PD-1 antibody formulation
EP17838513.4A EP3496753B1 (fr) 2016-08-09 2017-07-17 Formulation d'anticorps anti-pd-1

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/094094 WO2018027524A1 (fr) 2016-08-09 2016-08-09 Formule d'anticorps anti-pd-1.

Publications (1)

Publication Number Publication Date
WO2018027524A1 true WO2018027524A1 (fr) 2018-02-15

Family

ID=61161074

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2016/094094 WO2018027524A1 (fr) 2016-08-09 2016-08-09 Formule d'anticorps anti-pd-1.
PCT/CN2017/093141 WO2018028383A1 (fr) 2016-08-09 2017-07-17 Formulation d'anticorps anti-pd-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/093141 WO2018028383A1 (fr) 2016-08-09 2017-07-17 Formulation d'anticorps anti-pd-1

Country Status (9)

Country Link
US (1) US11130809B2 (fr)
EP (1) EP3496753B1 (fr)
JP (1) JP6848046B2 (fr)
CN (1) CN109562173B (fr)
AU (1) AU2017310916B2 (fr)
BR (1) BR112019001233B1 (fr)
CA (1) CA3030929C (fr)
ES (1) ES2969233T3 (fr)
WO (2) WO2018027524A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112839678A (zh) * 2019-07-18 2021-05-25 德尔塔菲制药股份有限公司 抗癌剂的效果增强剂
EP4088740A4 (fr) * 2020-01-06 2024-02-21 Shanghai Henlius Biotech, Inc. Formulation d'anticorps de récepteur 1 de mort cellulaire programmée et son utilisation

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018008867A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e seus usos
CN109498565B (zh) * 2018-12-27 2021-06-29 兴盟生物医药(苏州)有限公司 一种稳定的抗pd-1抗体制剂及其用途
JP6802598B1 (ja) 2019-07-18 2020-12-16 Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社 抗がん剤の効果増強剤
EP4076385A1 (fr) 2019-12-20 2022-10-26 Formycon AG Formulations d'anticorps anti-pd1
TW202130367A (zh) * 2020-01-15 2021-08-16 大陸商信達生物製藥（蘇州）有限公司 結合ｐｄ－１和ｐｄ－ｌ１的雙特異性抗體的製劑及其用途
KR20230026446A (ko) * 2020-06-19 2023-02-24 사이노셀테크 엘티디. 재조합 항-pd-1 단일클론 항체를 위한 안정한 제형
EP4359001A1 (fr) 2021-06-23 2024-05-01 Formycon AG Formulations d'anticorps anti-pd1
WO2024133625A1 (fr) 2022-12-21 2024-06-27 Formycon Ag Formulations d'anticorps anti-pd1
WO2024171082A1 (fr) 2023-02-16 2024-08-22 Sun Pharmaceutical Industries Limited Compositions de protéines stables d'anticorps anti-pd1

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011110604A1 (fr) * 2010-03-11 2011-09-15 Ucb Pharma, S.A. Anticorps pd-1
WO2012135408A1 (fr) * 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Formulations stables d'anticorps dirigés contre le récepteur humain pd-1 de la mort programmée et traitements associés
WO2015031667A2 (fr) * 2013-08-30 2015-03-05 Amgen Inc. Protéines de liaison à l'antigène gitr
WO2016044189A1 (fr) * 2014-09-15 2016-03-24 Genentech, Inc. Méthodes de traitement du cancer faisant appel à un antagoniste se liant à l'axe pd-1 et à des antagonistes se liant à l'il-17
WO2016070051A2 (fr) * 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Thérapie combinée pour le traitement d'une maladie
WO2016092419A1 (fr) * 2014-12-09 2016-06-16 Rinat Neuroscience Corp. Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
EP3530736A3 (fr) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques
KR20110096553A (ko) * 2008-11-28 2011-08-30 아보트 러보러터리즈 안정한 항체 조성물 및 이의 안정화 방법
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
ES2684921T3 (es) * 2010-05-10 2018-10-05 Intas Pharmaceuticals Limited Formulación líquida de polipéptidos que contienen un dominio Fc de una inmunoglobulina
PT3049441T (pt) * 2013-09-27 2020-01-21 Hoffmann La Roche Formulações de anticorpos anti-pdl1
CN104740612A (zh) * 2013-12-31 2015-07-01 上海中信国健药业股份有限公司 一种受体抗体融合蛋白的液体制剂
SG11201701149SA (en) 2014-07-18 2017-04-27 Advaxis Inc Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
US10695426B2 (en) * 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
WO2017024465A1 (fr) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Anticorps anti-pd-1

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011110604A1 (fr) * 2010-03-11 2011-09-15 Ucb Pharma, S.A. Anticorps pd-1
WO2012135408A1 (fr) * 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Formulations stables d'anticorps dirigés contre le récepteur humain pd-1 de la mort programmée et traitements associés
WO2015031667A2 (fr) * 2013-08-30 2015-03-05 Amgen Inc. Protéines de liaison à l'antigène gitr
WO2016044189A1 (fr) * 2014-09-15 2016-03-24 Genentech, Inc. Méthodes de traitement du cancer faisant appel à un antagoniste se liant à l'axe pd-1 et à des antagonistes se liant à l'il-17
WO2016070051A2 (fr) * 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Thérapie combinée pour le traitement d'une maladie
WO2016092419A1 (fr) * 2014-12-09 2016-06-16 Rinat Neuroscience Corp. Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TOPALIAN, S. L. ET AL.: "Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 366, no. 26, 28 June 2012 (2012-06-28), pages 2443 - 2454, XP055098235 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112839678A (zh) * 2019-07-18 2021-05-25 德尔塔菲制药股份有限公司 抗癌剂的效果增强剂
EP4088740A4 (fr) * 2020-01-06 2024-02-21 Shanghai Henlius Biotech, Inc. Formulation d'anticorps de récepteur 1 de mort cellulaire programmée et son utilisation

Also Published As

Publication number Publication date
BR112019001233A2 (pt) 2019-06-25
AU2017310916B2 (en) 2020-02-06
CN109562173A (zh) 2019-04-02
EP3496753A4 (fr) 2020-04-01
US20210040211A1 (en) 2021-02-11
AU2017310916A1 (en) 2019-03-07
EP3496753A1 (fr) 2019-06-19
BR112019001233B1 (pt) 2021-10-26
US11130809B2 (en) 2021-09-28
JP2019527712A (ja) 2019-10-03
WO2018028383A1 (fr) 2018-02-15
CA3030929C (fr) 2022-06-21
CA3030929A1 (fr) 2018-02-15
JP6848046B2 (ja) 2021-03-24
ES2969233T3 (es) 2024-05-17
EP3496753B1 (fr) 2023-11-22
CN109562173B (zh) 2022-09-02

Similar Documents

Publication Publication Date Title
US11130809B2 (en) PD-1 antibody formulation
KR102397713B1 (ko) 안정한 액체 약제학적 제제
RU2731418C2 (ru) Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине
ES2413090T3 (es) Formulación subcutánea de anticuerpo anti-HER2
JP5631591B2 (ja) 安定な抗体製剤
CN105209069B (zh) 抗体配制剂
TW200306205A (en) Lyophilised preparation comprising antibodies against the EGF receptor
RU2704611C2 (ru) Составы на основе антител
JP2022521624A (ja) 抗ｃｄ４７抗体を含む製剤、その調製方法および使用
US20220041709A1 (en) Human anti-il-33 monoclonal antibody-containing pharmaceutical composition
WO2021147854A1 (fr) Préparations d'anticorps monoclonaux anti-tigit recombinants entièrement humains, leur procédé de préparation et leur utilisation
US20210315813A1 (en) Stable Liquid Pharmaceutical Preparation
CN109498565B (zh) 一种稳定的抗pd-1抗体制剂及其用途
CN111094342A (zh) 用于治疗TNFα相关疾病的方法
EP4079294A2 (fr) Formulation stable et de haute concentration de l'anticorps nimotuzumab
CN116077646A (zh) 一种抗冠状病毒s蛋白的抗体制剂及其制备方法和用途
NZ748101B2 (en) Stable liquid pharmaceutical preparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16911979

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 02/08/2019)

122 Ep: pct application non-entry in european phase

Ref document number: 16911979

Country of ref document: EP

Kind code of ref document: A1